Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Synaffix to Present Key ADC Technology Data on SYNtecan E Linker-Payload at World ADC Conference

Oct 13, 2021

Virtual poster presentation shows complete tumor regression and high tolerability of a SYNtecan E™ based ADC SYNtecan E™ linker-payload is a potent exatecan-based, DNA topoisomerase 1 inhibitor developed by Synaffix Data underscores ability of Synaffix’s technologies...

Third ADC with Synaffix’s Technology Enters Clinical Development

Sep 29, 2021

AMSTERDAM, NETHERLANDS, September 29, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its...

BGV Expands Team with the Appointment of a Partner and Venture Partner

Sep 14, 2021

Naarden, The Netherlands, 14 September 2021 – BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma, today announces the appointment of Keno Gutierrez as Partner, and Wouter Verhoeven as Venture Partner. Collectively these two appointments...

Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology

Aug 17, 2021

First-in-human study evaluating CIT-013, a humanized monoclonal antibody targeting Neutrophil Extracellular Traps (NETs)CIT-013 binds to citrullinated Histones H2A and H4CIT-013 inhibits NET formation, promotes tissue NET clearance, and hence blocks the...

News overview

Next events

7-8 Oct Sachs 20th Annual Biotech in Europe Forum

Aug 27, 2021

The 20th Annual Biotech in Europe (BEF) Forum is recognised as the leading international Stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws...

19 – 21 October BioEntrepreneurship Summit 2021

Aug 27, 2021

At the BioEntrepreneurship Summit 2021, founders, startup enthusiasts, experienced entrepreneurs, corporates and investors will come together to foster the exchange of knowledge, to inspire and to empower, and to celebrate life science entrepreneurship. In 2021, the...

25-28 October – BioEurope

Jun 15, 2021

Building Partnerships in a Digital Age - Facilitating the flow of global life science deals. The international BIO-Europe® 2021 gathering will be held digitally, standing tall in this time of insecurity, to execute on its pivotal role in bringing the global biopharma...

Event overview